Objective: Establish a robust cardiac stem cell isolation and culture protocol to consistently generate 3 distinct stem cell populations from a single human heart biopsy. 
I dentification and selection for optimal stem cell type(s) remains a critical issue for successful therapeutic implementation of myocardial regeneration in patients experiencing heart failure. Cell populations from a variety of tissue sources, including bone marrow mononuclear cells, skeletal myoblasts, hematopoietic and endothelial progenitors, and induced pluripotent or embryonic stem cells, have been extensively tested for their ability to regenerate lost myocardium. 1, 2 However, clinical trial outcomes repeatedly fall short of expectations raised by preclinical animal studies, [3] [4] [5] [6] [7] [8] prompting concern about the translational impact of experimental models. Nevertheless, there is growing acceptance of the new dogma that the adult mammalian heart is capable of cellular replacement throughout life and in response to pathological injury, including the cardiomyocyte population. 9 Myocardial regeneration is facilitated by resident stem cells that activate endogenous tissue repair by both direct and indirect contribution to cellular replacement of cardiomyocytes, smooth muscle cells, and endothelial cells. Considering the heart as a self-renewing organ opens up exciting possibilities for therapeutic intervention by cellular activation to promote regenerative processes. muscle and endothelial cells. Relative contributions of divergent resident cardiac stem cell types must be appreciated and delineated to maximize therapeutic potential of cell-mediated repair. Coordinated action of multiple cardiac stem cell types forms the basis for normal myocardial biology and therefore will likely be essential to achieve clinically meaningful restoration of tissue structure and function in the wake of pathological damage. Regardless of whether the ultimate effectors of repair are derived from an adoptively donated cell population or recruited from the endogenous pool(s) of resident cells, it is imperative to establish a working understanding of interactions and contributions of the distinct stem cell types participating in mediation of myocardial homeostasis and repair. Toward that goal, a simple and cost-effective protocol to separate and enrich multiple cardiac stem cells into distinct subsets is essential. On the basis of established precedents, 3 such resident adult cardiac stem cells include cardiac progenitor cells (CPCs), and supportive cell types comprised mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) that can be differentially separated based on surface marker expression profiling.
Cardiac stem cells were originally isolated in the adult rat heart based on tyrosine-protein kinase Kit (c-Kit) or CD117 expression and were found to lack hematopoietic lineage markers. 10 A similar population of c-Kit + CPCs was identified in the adult human heart, 11, 12 prompting clinical testing to assess their potential efficacy for enhancing myocardial regeneration. 13, 14 Early patient results have been encouraging showing improved heart function; however, advanced age, comorbidities, and genetic factors in patients with heart failure constrain the regenerative capacity of CPCs. Rejuvenation of senescent CPCs, such as with genetic modification, 15, 16 repeated cell administrations, 17 or in conjunction with additional supportive cell types, 18 may improve outcomes for a substantial patient population possessing functionally impaired stem cells.
Stromal MSCs are a supportive cell that contributes to regeneration by secretion of paracrine factors that activate endogenous stem cells, promote angiogenesis, protect cardiomyocytes, and reduce scar formation. [19] [20] [21] MSCs are multipotent stem cells that give rise to skeletal myoblasts, chondrocytes, and adipose tissue. 19, 22 Adherent MSCs express cell surface markers CD73, CD105, CD29, CD44, and CD90, while lacking CD45 that is expressed by hematopoietic stem cells. 23 Lack of major histocompatibility complex II expression allows MSCs to evade host immune responses and overcome host rejection 19, 24 leading to their suggested use for allogeneic transplantation into patients. 25, 26 EPCs were formerly defined as progenitor cells positive for both the hematopoietic stem cell marker CD34 and the endothelial 
Novelty and Significance
What Is Known?
• Stem cell transplantation for heart repair shows efficacy in both animal studies and clinical trials, but relative actions and synergism between distinct myocardial-derived stem cell populations remain obscure.
• Cardiac progenitor cells resident within the human myocardium promote replacement of cardiomyocytes and vasculature (smooth muscle and endothelial cells) after injury.
• Mesenchymal stem cells contribute to regeneration primarily through paracrine secretion.
• Endothelial progenitor cells contribute to microvessels and vascular structure.
What New Information Does This Article Contribute?
• We describe a simple and cost-effective protocol to isolate and enrich for multiple human cardiac stem cell populations from a single myocardial sample that maintain their individual unique phenotypic properties during ex vivo cell culture.
• Isolation of multiple stem cell types from a single human heart sample allows for concurrent study of cell interactions and development of novel techniques to facilitate understanding and implementation of cardiac regenerative medicine.
Desperate unmet need to alleviate the suffering and burden of heart failure has understandably prompted rapid progression to clinical trial while foregoing deeper fundamental understanding of cardiac stem cell biology or identification of which cells most effectively mediate repair and regeneration. Our protocol paves the way for greater understanding and improved outcomes through isolation of multiple cardiac cell populations from a single tissue sample. This approach facilitates studies to determine which stem cell population(s) hold the most promise for cardiac regeneration studied either individually or in combination. Our sorting protocol allows for isolation of c-Kit + cardiac progenitor cells, cKit 30 EPCs promote paracrine-dependent vasculogenesis and angiogenesis and form microvessels on transplantation in vivo. 31 However, these microvessels regress without support from MSCs to allow vessel maturity. 32 For this reason, combinatorial cell therapies have been suggested for the treatment of heart failure in hopes of synergistic effects, 18 but isolation and examination of multiple enriched stem cell subpopulations from a single human heart has not been previously performed.
Knowledge and understanding of myocardial regenerative mechanisms will be facilitated by adoption of the protocol to derive 3 resident cardiac stem cell populations from adult heart biopsies procured during left ventricular assist device (LVAD) implantation described herein. Our sorting protocol allows for isolation of cKit + CPCs, c-Kit
+ EPCs, and c-Kit
+ MSCs from patients of varying age and sex. Here, we show that these 3 cell populations maintain their unique phenotypic properties during ex vivo cell culture. Phenotypically, these cells show distinct morphology, growth kinetics, cell surface marker and gene expression profiles, and cardiac lineage potential. Isolation of multiple cells types from a single tissue source will allow for concurrent study of cell interactions, empower studies using cells derived from the target human heart failure population that will be involved in regenerative therapy, and expand the repertoire of possibilities for manipulation and modification of stem cells to treat cardiovascular disease. Therefore, the protocol and initial characterizations in this report represent an important and valuable technical advance in the development of novel techniques to facilitate understanding and implementation of regenerative medicine.
Methods

Human Cardiac Stem Cell Isolation
Cardiac biopsies were obtained from patients undergoing LVAD implantation. The National Institutes of Health guidelines for human subject research are consistent with Institutional Review Board exemption based on the use of tissues that are waste discards from normal and routine clinical procedures of LVAD surgery (45 CFR 46.101). After excision, cardiac tissue remained on ice in cardioplegic solution until processed. Fatty tissue was excised, and remaining cardiac tissue was suspended in basic buffer (15 mL) and minced into 1 mm 3 pieces. After mincing, tissue and basic buffer were collected in 50 mL Falcon tube. Digestive solution containing collagenase, type II 225 U/mg dry weight (Worthington, No. LS004174; Bio Corp, Lakewood, NJ), was dissolved in basic buffer (2-2.5 mg/mL) and incubated with tissue pieces for 1.5 to 2 hours at 37°C with continuous shaking. Digestion solution was refreshed at the 1-hour time point, and resulting suspensions were centrifuged at 350 g for 5 minutes and resuspended in CPC media (Table) . + fraction was divided as follows: half the population was suspended in CPC media (Table) , and the other half was suspended in EPC media (Table) . The cKit − population was further incubated with CD90/CD105-labeled beads and sorted according to the manufacturer's protocol (Miltenyi Biotec, No. 130-096-253/130-051-201). Cells positive for CD90/CD105 were suspended in MSC media (Table) . To isolate an EPC population, at 1 week, the c-Kit + population plated in EPC media was further sorted using CD133-labeled beads and sorted according to the manufacturer's protocol (Miltenyi Biotec, No. 130-097-049). All cells were cultured at 37°C in CO 2 incubator in their respective growth media. CPC and EPC were split 1:2 when they reached 60% to 70% confluency. MSC were split 1:2 when they reached 90% confluency. Patient information for the 5 cardiac samples used in this study can be found in Online Table III . All cells used in this study were midpassage (passages 5-9).
Quantitative Reverse-Transcriptase Polymerase Chain Reaction and Bioinformatics
Total RNA was isolated from cardiac stem cell populations using Quick-RNA MiniPrep kit (Zymo Research, No R1055) according to manufacturer's protocol. Five-hundred ng of RNA was used to generate complementary DNA (cDNA) using an iScript cDNA Synthesis kit (Bio-Rad Laboratories, No. 170-8891). The amplified cDNA was diluted at a ratio of 1:10 in DNase-and RNase-free water. Quantitative reverse-transcriptase polymerase chain reaction (PCR) were completed using iQ SYBER Green (Bio-Rad Laboratories, No. 170-8882) on a CFX Real-Time PCR Detection System (BioRad). cDNA was amplified using primers specific to genes of interest (Online Table II ). The comparative or ΔΔCt method of quantitative reverse-transcriptase PCR data analysis was used to analyze samples; variability in cDNA concentration was normalized using 18S. Hierarchical clustering and supervised clustering for gene expression profiling were performed using Expander 7.1 software.
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Immunocytochemistry
Cardiac stem cell populations were plated on 2-well chamber glass slides (10 000 cells per well) in their respective growth media (Table) for a minimum of 24 hours. After incubation, slides were washed with PBS and fixed in 4% paraformaldehyde for 5 minutes at 4°C. After fixation, the slides were washed twice with PBS and permeabolized in PBS plus 0.1% Triton X-100, 0.1 mol/L Glycine for 3 minutes, then washed once with PBS, and blocked with TNB buffer (1X TN [Tris-HCl, NaCl] buffer, 5 µg/mL blocking reagent [PerkinElmer, No. FP1012]) for 30 minutes. Primary antibodies were diluted in TNB (Online Table I ) and incubated overnight at 4°C. The following day, slides were washed twice with PBS. Fluorescently conjugated secondary antibodies were diluted in TNB (1:200) and incubated 1.5 hours at room temperature. For c-Kit staining, a horseradish peroxidase-linked secondary antibody (1:500) was used, followed by tyramide signal amplification (1:50) (PerkinElmer, No. NEL753001KT). After washing twice with PBS, DAPI was included in a final wash to fluorescently label the nuclei, and slides were coverslipped with Vectashield mounting reagent (Vector Laboratories, No. H-1000). All slides were imaged using a Leica TCS SP8 confocal microscope. A table of antibodies and dilution ratios is available in Online Table I .
Cell Morphology Measurement
Cardiac stem cell populations were imaged using a Leica DMIL inverted tissue culture phase-contrast microscope. Cell morphology was measured by tracing the outline of the cells using Image J software. The 3 measurements analyzed were area, roundness, and length/width ratios. Length/width ratios were calculated by dividing Feret/Min Feret measurements. A minimum of 30 cells was measured per cell line.
Cell Proliferation Assay
Cell populations were plated in quadruplicate (1000 cells per well) in a 96-well black flat bottom plate with 100 µL/well of their respective growth media. Cell proliferation rate was determined using a CyQUANT Direct Cell Proliferation Assay (Thermo Fisher Scientific, No. C35011) on days 0, 1, 3, and 5. Doubling times were calculated based on periods of exponential growth using a population doubling time online calculator (http://www.doubling-time.com/ compute_more.php).
Flow Cytometry
For live cell analysis, single cells were suspended in 100 μL wash buffer (PBS plus 0.5% bovine serum albumin) and incubated with primary antibody (Online Table I 
300 μL wash buffer was added post-secondary incubation, and the cells were analyzed by flow cytometry with a BD FACSCanto instrument. Unstained and isotype controls were used to establish baseline fluorescence levels. Data were analyzed by Flow Jo software (BD Biosciences). A minimum of 10 000 cell counts was analyzed. Because of low cell count for H13-066 MSC, the c-Kit count was 5000.
Matrigel Tube Formation
Growth factor-reduced matrigel (Corning, No. 356231) was used to coat a 96-well flat bottom plate (50 µL/well) and incubated for 30 minutes at 37°C. Cardiac stem cell populations were plated in duplicate (5000 cells per well) suspended in 100 µL/well of EPC basal medium (Table) and incubated at 37°C in CO 2 incubator. Cell tube formation was imaged using a Leica DMIL inverted tissue culture phase-contrast microscope 12 to 16 hours after plating.
MSC Colony-Forming Unit-Fibroblast Assay
Cells were suspended in colony-forming unit-fibroblast assay medium: Dulbecco modified Eagle's medium low glucose (Thermo Fisher Scientific, No. 11054-020) with 10% fetal bovine serum, 2 mmol/L L-Glutamine and gentamicin (10 mg/mL), and plated at 200 cells per 100 mm. Medium changed every 3 days, and after 14 days of growth, dishes were washed with PBS and incubated in crystal violet at room temperature for 30 minutes. Solution removed by 4 washes of PBS. After dishes were dry, colonies were enumerated for each plate. A minimum of 3 dishes plated per cell line.
Multilineage Mesenchymal Differentiation Potential
The potential for osteogenesis, adipogenesis, and chondrogenesis differentiation was assessed for the 3 cardiac stem cell populations using StemPro Differentiation Kits following manufacturer's proto- 
Statistical Analysis
Data expressed as mean±SEM. Statistical analyses of multiple groups were assessed by 1-way ANOVA with Bonferroni post hoc test. Multiple groups over time were analyzed by 2-way ANOVA. Statistical analysis was performed using GraphPad Prism version 5.0 software. The Pearson product-moment correlation coefficient was calculated using Microsoft Excel 2010. Experiments were performed in triplicate unless stated otherwise. A P value of <0.05 was considered statistically significant.
Results
Isolation of 3 Distinct Cardiac Stem Cell Populations
The 3 different cardiac stem cell populations were isolated and expanded as described in the Methods: Human Cardiac Stem Cell Isolation (Figure 1) . At the time of extraction, the c-Kit − MSC population comprises 90% to 95% of our isolated stem cell pool, whereas c-Kit + cells comprise 5% to 10% of the isolated cells. One week later, roughly half of the c-Kit + cells are also positive for the endothelial progenitor marker CD133 + .
Distinctive Cell Morphology Among Cardiac Stem Cell Populations
After expansion ex vivo, midpassage cells were assessed for morphometrics. Phase-contrast imaging (Figure 2A ; Online Figure I ) measured parameters of area, roundness, and length/ width ratio. MSC area is significantly larger (23 301±1018) relative to both CPC (7435±358) and EPC (4738±202; Figure 2B ). EPCs are significantly more round (EPC, 0.57±0.016; CPC, 0.26±0.012; MSC, 0.38±0.016; Figure 2C ), whereas CPCs show increased length/width ratio (CPC, 4.2±0.16; EPC, 2.0±0.081; MSC, 3.0±0.12). Representative examples of cultures of the 3 cell types show close clustering of morphometric parameters (Online Figure II) with minor variation between individual patients.
Cell Population Kinetics Vary by Cell Type
Population growth kinetics was determined by CyQuant proliferation assay ( Figure 3A through 3C) . The MSC population exhibited slowest proliferation rate (doubling time: 119±35 hours) in agreement with previous studies using midpassage MSC populations. [34] [35] [36] CPCs and EPCs show markedly faster proliferation rates (doubling times: CPC, 33±2 hours; EPC, 35±7 hours; Figure 3D and 3E). Cell type growth kinetics varies by patient indicative of heterogeneity in cell biology between patient isolates (Online Figure III) .
Flow Cytometry Analysis of Markers Expressed After In Vitro Culture
Persistence of markers used to isolate the cardiac subpopulations was analyzed by flow cytometric analysis of single cell 
Immunocytochemistry Corroboration of Flow Cytometry Data
Immunofluorescence microscopy was used to assess endogenous expression levels of the panel of markers used for stem cell isolation. Expression of c-Kit in CPCs was uniformly high, whereas c-Kit expression was comparatively low in MSCs. Although a subset of the EPC population (marked by asterisks) expressed high levels of c-Kit, the majority expressed low to undetectable levels ( Figure 5A ). CD133 was prominently expressed by all 3 cells types ( Figure 5B ), consistent with flow cytometry data. Antibody labeling confirmed clear expression of mesenchymal markers CD90 and CD105 by the MSC population. Both mesenchymal markers were barely detectable above background in the EPC population with very low immunolabeling for CD105. Although CPCs expressed CD105, CD90 level in CPCs was relatively low in comparison to the MSC population ( Figure 5C ).
Gene Expression Profiles Show That EPCs Diverge From CPCs and MSCs
Transcriptional signatures for each cell type from various patients was performed using quantitative reverse-transcriptase PCR focused on 3 groups of genes: (1) growth factors and cytokines, (2) extracellular matrix proteins, and (3) inflammatory factors (Online Table II 
In Vitro Lineage Assessment and Comparison to Noncardiac Controls
Tube formation assay using growth factor-reduced Matrigel demonstrates angiogenic potential of the 3 cardiac stem cells in vitro. Ability to form tubular networks varied among patients and cell types; with only a few CPC lines being able to form rudimentary tubules ( Figure 7A ), EPCs were able to form robust tubular networks within 15 hours ( Figure 7B ) similar to human umbilical vein endothelial cell (HUVEC) control (data not shown), whereas MSCs could not form tubular structures, instead producing star-burst structures ( Figure 7C ). Multilineage mesenchymal differentiation assays to determine adipocyte, chondrocyte, and osteocyte potential were performed using MSC cultures (Online Figure VIII) . Similar to bone marrow-derived MSCs (bMSCs), cardiac-derived MSCs differentiate into adipocyte, chondrocyte, and osteocyte lineages, whereas EPCs and CPCs did not exhibit phenotypic characteristics of fully committed cell types. Cardiac-derived MSCs showed levels of major histocompatibility complex class I and class II, and costimulatory molecules comparable to bMSC (Online Figure IX) , and produce colony-forming units (data not shown).
HUVECs and bMSCs were used to assess the potential of cardiac stem cell commitment toward angiogenic or smooth muscle fate at the transcript level. HUVECs and EPCs expressed the highest levels of PECAM-1 (HUVEC, 1,967±106; EPC, 181±47) with respect to either CPCs (1.9±0.69) or MSCs (0.85±0.25; Figure 7D ). SMA (smooth muscle actin) is expressed by both bMSCs (1.0±0.12) and cardiac MSCs (52.67±10.06), and to a lesser extent CPCs (18.60±7.27). Both the EPCs and HUVECs expressed near undetectable levels of SMA (EPC, 0.04±0.01; HUVEC, 0.01±0.01; Figure  7E ). GATA4 (GATA binding protein 4) is expressed by the adult cardiomyocytes (22.19±0.06) and to a lesser degree by the CPCs (3.6±0.91). The other cell types showed lower expression of GATA4 (EPC, 3.09±0.31; MSC, 1.57±0.34; Figure 7F ).
Discussion
Unbiased sampling of tissue biopsies from heart failure patients undergoing LVAD implantation represents an ideal source for tissue to isolate and study characteristics of CPCs, EPCs, and MSCs in the context of decompensated heart failure. LVAD recipients on destination therapy are desperately in need of regenerative therapy as the only other available option for treatment is cardiac transplantation. In an effort to improve the rather modest outcomes of current cell-based regenerative medicine intervention, the use of multiple cell types in combination or sequentially could enhance efficacy. Indeed, experimental animal studies support the premise of combining CPC and MSC to enhance beneficial effect, 18 and ongoing clinical trials are moving this concept into patients. However, these studies are focused on allogeneic approaches that limit survival, engraftment, and persistence of the donated cell population. The protocol described in this report allows for simultaneous isolation of 3 distinct cell populations from a single tissue sample: CPC, MSC, and EPC. Each cell type exhibits characteristics that render them desirable to promote regenerative repair. EPCs promote vasculogenesis and angiogenesis and differentiate into mature endothelial cells. In vivo MSCs have been shown to contribute to endogenous regeneration by secretion of paracrine factors that activate endogenous stem cells, promote angiogenesis, protect cardiomyocytes, and reduce scar formation. [19] [20] [21] In animal models, transplanted CPCs give rise to cardiomyocytes, smooth muscle cells, and endothelial cells, 40, 41 but lack the power of MSCs to activate and recruit endogenous stem cells. For this reason, combinatorial cell therapies have been advanced in hopes of initiating synergistic effects in myocardial repair, but no one to date has attempted to inject multiple stem cells expanded solely from the human heart. With this protocol, combinatorial studies can be performed using 3 cardiac cell populations isolated from a single heart. These cells can be studied combinatorial or individually to better elucidate how these distinct cell populations regulate and contribute to cardiac regeneration after ischemic injury.
Cardiac stem cell populations play intrinsically distinct roles in cardiac regeneration. Insight into what makes each cell type unique will translate to superior clinical application depending on disease state of the patient. For example, for chronic ischemia, the primary intent may be to salvage the cardiomyocytes and improve blood supply. Consequently, using a cell type that induces vascular regeneration such as EPCs would be important. On the other hand, if the goal were to replace lost cardiomyocytes, perhaps CPCs supported by MSCs would favor activation of endogenous cardiomyocytes and exhibiting inherent cardiomyogenic potential. Alternatively, coinjection of all 3 cardiac stem cell types may provide the most robust reparative and regenerative outcome. Achieving long-lasting myocardial benefits likely requires the interaction of multiple cardiac cell types, and testing this hypothesis is the focus of ongoing experimental studies.
The CPC, MSC, and EPC populations can be reproducibly isolated using samples obtained from multiple patients with varying age and disease causes ≤84 years of age. Patients presented with a range in cardiomyopathies and comorbidities, including diabetes mellitus and coronary artery disease, and heavy smokers and drinkers. Success rate of isolating the 3 cell populations was 80% to 90%. For a minority of patient, samples received the ex vivo culture resulted in outgrowth from only 2 populations, which we attribute to many possible factors, including tissue size, culture error, or absence of a particular cell type in the biopsy sample received. Not to be overlooked, another potential explanation for inability to expand a particular cell type could be correlated to a patient's disease state, and this will be interesting to examine in future studies. We were unable to establish such relationships owing to the relatively small number of patients assessed in our isolation sampling. While showing some variation, consistent trends are evident with regard to cell morphology (Figure 2 ), growth kinetics (Figure 3) , and gene profiles ( Figure 6 ). Specifically, gene expression levels for cytokines, extracellular matrix proteins, paracrine, and inflammatory factors clustered based on the 3 cardiac stem cell lineages. EPCs were transcriptionally distinct from CPCs and MSCs that possessed more similar profiles ( Figure 6 ). Transcript profiles of EPCs isolated from the heart were comparable to observed profiles in HUVECs (an established endothelial cell line), and cardiac EPCs also retain the capacity to form tubular networks on Matrigel, consistent with endothelial cell phenotypic properties (Figure 7) . This protocol provides detailed culture procedures that will allow for stem cell maintenance evidenced by preservation of stem cell markers (Figure 4 ; Figure 5 ). Key factors for successful propagation and expansion ex vivo are culture conditions and growth medium. Each cell type has its own preferential plating density, and depending on cell type, differentiation and senescence can occur with prolonged culture 15, 34 or because of cell-cell contact if cultured to confluency. 42, 43 CPCs and EPCs are successfully cultured at 50% to 70% confluency. On the other hand, MSCs prefer close contact with neighboring cells (70% to 90% confluency), seem cytopathic, and grow extremely slow when cultured <60% confluency.
Although the initial relative abundance of MSCs is higher compared with either CPCs or EPCs after isolation, the latter 2 populations proliferate quickly ( Figure 3 ) and senesce at a later passage than MSCs. The MSC population in most patient samples slows down proliferation around passages 8 to 10 and will completely senesce a few passages later. Considering the demands of cell manufacturing for clinical utilization, ≈100 million cells can be produced by passage 10. The majority of CPC and EPC lines continue to proliferate until passages 15 to 20, and thus, these 2 cell types can readily produce hundreds of millions of cells.
The protocol described herein is a highly reproducible and straightforward method independently conducted by multiple individuals at varied training levels ranging from graduate to postdoctoral level. In addition, the procedure is amenable to being performed under a wide variety of experimental conditions. An example already initiated in our laboratory includes splitting a single cardiac biopsy in half and conducting initial isolation under normoxic versus hypoxic conditions to study altered oxygen concentration and resulting phenotypic changes that occur in the isolated cardiac stem cell populations. Other applications could include variation in media formulation, such as glucose or growth factor supplementation, or examining differences caused by extracellular matrices and biologically coated surfaces.
Desperate unmet need to alleviate the suffering and burden of heart failure has understandably prompted a rapid progression into clinical trials while necessarily foregoing a deeper fundamental understanding of cardiac stem cell biology or identification of which cell or combination of cells yields the most efficacious outcome to mediate repair and regeneration in vivo. Initial clinical trials performed using bMSCs were quickly pursued, in part owing to relative ease of isolation and established protocols, but yielded generally disappointingly modest myocardial recovery. 44 The challenging frontier for myocardial regenerative medicine with the ever-expanding tapestry of potential interventional strategies requires careful analysis of critical factors in cell biology such as self-renewal potential, survival, and mechanisms that allow particular cell population(s) to repopulate the damaged myocardium more effectively than others. Each individual cell type may be specialized to perform in a specific context, and combinations of cell types likely will exert actions through concerted cooperative networking that any 1 single cell type cannot provide. Equipped with this basic understanding, secondary considerations of cell dosage, timing, and delivery approach will need to be optimized. These concepts represent a small sampling of the nearly limitless conceptual possibilities that lie ahead for myocardial regenerative research. All journeys begin with a single step, and this protocol paves the way by isolating multiple cardiac cell populations that can be studied individually or combinatorial so that the field of cardiac stem cell therapy can come to a better understanding on which stem cell population(s) hold the most promise for cardiac regeneration.
